These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25088576)

  • 1. Multidrug resistance-associated protein 3 confers resistance to chemoradiotherapy for rectal cancer by regulating reactive oxygen species and caspase-3-dependent apoptotic pathway.
    Yu Z; Zhang C; Wang H; Xing J; Gong H; Yu E; Zhang W; Zhang X; Cao G; Fu C
    Cancer Lett; 2014 Oct; 353(2):182-93. PubMed ID: 25088576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
    Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
    Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAD18 may function as a predictor of response to preoperative concurrent chemoradiotherapy in patients with locally advanced rectal cancer through caspase-9-caspase-3-dependent apoptotic pathway.
    Yan X; Chen J; Meng Y; He C; Zou S; Li P; Chen M; Wu J; Ding WQ; Zhou J
    Cancer Med; 2019 Jun; 8(6):3094-3104. PubMed ID: 31033216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of ATP-binding cassette subfamily C member 4 increases sensitivity to neoadjuvant radiotherapy for locally advanced rectal carcinoma.
    Yu ZQ; Zhang C; Wang H; Lao XY; Chai R; Gao XH; Cao GW; Fu CG
    Dis Colon Rectum; 2013 May; 56(5):600-8. PubMed ID: 23575399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance and molecular mechanism of ATP-binding cassette subfamily C member 4 in resistance to neoadjuvant radiotherapy of locally advanced rectal carcinoma.
    Yu Z; Zhang C; Chai R; Du Y; Gao X; Xing J; Yu E; Zhang W; Zhang X; Cao G; Fu C
    PLoS One; 2014; 9(1):e85446. PubMed ID: 24454870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
    Edden Y; Wexner SD; Berho M
    Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer.
    Flanagan L; Kehoe J; Fay J; Bacon O; Lindner AU; Kay EW; Deasy J; McNamara DA; Prehn JH
    Radiat Oncol; 2015 Jun; 10():131. PubMed ID: 26071313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
    Li CF; He HL; Wang JY; Huang HY; Wu TF; Hsing CH; Lee SW; Lee HH; Fang JL; Huang WT; Chen SH
    J Clin Pathol; 2014 Dec; 67(12):1056-61. PubMed ID: 25271212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.
    Wheeler JM; Dodds E; Warren BF; Cunningham C; George BD; Jones AC; Mortensen NJ
    Dis Colon Rectum; 2004 Dec; 47(12):2025-31. PubMed ID: 15657650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study.
    Hongo K; Kazama S; Tsuno NH; Ishihara S; Sunami E; Kitayama J; Watanabe T
    World J Surg Oncol; 2015 Jan; 13():7. PubMed ID: 25622595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial.
    Bujko K; Michalski W; Kepka L; Nowacki MP; Nasierowska-Guttmejer A; Tokar P; Dymecki D; Pawlak M; Lesniak T; Richter P; Wojnar A; Chmielik E;
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):369-77. PubMed ID: 17118570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
    Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
    Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer.
    Avoranta ST; Korkeila EA; Ristamäki RH; Syrjänen KJ; Carpén OM; Pyrhönen SO; Sundström JT
    Hum Pathol; 2013 Jun; 44(6):966-74. PubMed ID: 23332924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation.
    Ruby JA; Leibold T; Akhurst TJ; Shia J; Saltz LB; Mazumdar M; Riedel ER; Larson SM; Guillem JG
    Dis Colon Rectum; 2012 Apr; 55(4):378-86. PubMed ID: 22426260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of peroxiredoxin I in rectal cancer and related to p53 status.
    Chen MF; Lee KD; Yeh CH; Chen WC; Huang WS; Chin CC; Lin PY; Wang JY
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):868-78. PubMed ID: 20732753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
    Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
    Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
    Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of long interval between hyperthermochemoradiation therapy and surgery for rectal cancer on apoptosis, proliferation and tumor response.
    Kato T; Fujii T; Ide M; Takada T; Sutoh T; Morita H; Yajima R; Yamaguchi S; Tsutsumi S; Asao T; Oyama T; Kuwano H
    Anticancer Res; 2014 Jun; 34(6):3141-6. PubMed ID: 24922685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.